In a regulatory filing, Procept BioRobotics (PRCT) disclosed that its director Frederic Moll bought 20K shares of common stock on August 13th in a total transaction size of $785K.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRCT:
- Buy Rating for PROCEPT BioRobotics: Growth Potential and Stability Amid Sales Beat and Improved Guidance
- Procept Biorobotics Reports Strong Q2 Growth Amid Challenges
- Procept Biorobotics Corp.’s Aquablation Therapy: A Promising Update for Prostate Cancer Treatment
- Procept BioRobotics price target lowered to $55 from $80 at Piper Sandler
- PROCEPT BioRobotics Reports Strong Q2 2025 Growth